|
| | HYDROXY PENTOXIFYLLINE Basic information |
| | HYDROXY PENTOXIFYLLINE Chemical Properties |
| Melting point | 123-125°C | | Boiling point | 511.2±56.0 °C(Predicted) | | density | 1.32±0.1 g/cm3(Predicted) | | storage temp. | Refrigerator | | solubility | DMSO: soluble | | form | solid | | pka | 15.22±0.20(Predicted) | | color | white | | Stability: | Stable for 1 year from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20° for up to 2 months. |
| | HYDROXY PENTOXIFYLLINE Usage And Synthesis |
| Description | Lisofylline (6493-06-7, racemic) displays anti-inflammatory activity. Regulates immune cell function and autoimmune response by inhibition of IL-12 signalling and cytokine production.1 Protects pancreatic beta cells and prevents type I diabetes in non-obese diabetic mice.2 Lisofylline reduces LPS-induced TNF alpha levels in CD-1 mice.3?Cell permeable. | | Chemical Properties | White Solid | | Uses | A major oxidative metabolite of Pentoxifylline. A potent inhibitor of phosphatidic acid generation (IC50=0.6uM). Protects mice from endotoxic shock and attenuates sepsis-induced acute lung injury in pig. | | Definition | ChEBI: 1-(5-hydroxyhexyl)-3,7-dimethyl-3,7-dihydro-1H-purine-2,6-dione is a dimethylxanthine that is 3,7-dihydro-1H-purine-2,6-dione which is substituted at positions 1,3 and 7 by a 5-hydroxyhexyl group, methyl group and methyl group, respectively. It is a secondary alcohol and a dimethylxanthine. | | Brand name | ProTec (Cell
Therapeutics). | | in vitro | (±)-lisofylline is a potent anti-inflammatory agent in which only the (-) optical isomer is biologically active. (±)-lisofylline was found to inhibit the generation of phosphatidic acid from cytokine-activated lysophosphatidic acyl transferase. (±)-lisofylline could also suppress the production of the proinflammatory cytokine ifn-γ, inhibit il-12-mediated stat-4 activation, as well as enhance glucose-stimulated β-cell insulin secretion [1]. | | in vivo | in a previous study, lisofylline was administered to female non-obese diabetic mice for 3 weeks. cytokines and blood glucose concentrations were monitored. histology and immunohistochemistry were also carried out in pancreatic sections. results showed that lisofylline was able to suppress ifn-γ production, reduce the onset of insulitis and diabetes, and inhibit diabetes [1]. | | References | 1) Yang?et al. (2005),?Lisofylline: a potential lead for the treatment of diabetes; Biochem. Pharmacol., 69?1
2) Yang?et al. (2002),?The anti-inflammatory compound lisofylline prevents Type I diabetes in non-obese diabetic mice; Diabetologia,?45?1307
3) Wyska?et al. (2010),?Pharmacokinetic-pharmacodynamic modeling of methylxanthine derivatives in mice challenged with high-dose lipopolysaccharide; Pharmacology,?85?264 |
| | HYDROXY PENTOXIFYLLINE Preparation Products And Raw materials |
|
